Apollo Hospitals Enterprise Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APOLLOHOSP, BSE:508869 Apollo Hospitals Enterprise Ltd.

Apollo Hospitals Enterprise Ltd.

14 Feb 2020

7051.00

0.59%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

Target

ICICI Securities Limited

Healthcare expansion moderates; focus on asset sweating Rapid expansion and maturity of older hospitals has kept the overall growth tempo at 12-14% per annum. After an intense capex cycle, especially during FY14-18, the company is focusing on the profitability and return ratios with calculated capex moderation. This has reflected in a marked improvement in both EBITDA margins and RoCE. The new hospitals and ventures are turning profitable ahead of schedule on the back of a judicious case mix besides better occupancy and other matrix. We expect healthcare sales to...

Apollo Hospitals Enterprise Ltd.'s price crossed above 50Day SMA today

Apollo Hospitals Enterprise Ltd.

10 Dec 2019

7051.00

0.59%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

ICICI Securities Limited

The pharmacy business (40% of FY19 revenues) has grown at ~22% CAGR in the last five years on the back of consistent addition of new pharmacies and timely closure of non-performing pharmacies. FY19 margins were at 5.2%. We expect the pharmacy business to grow at ~15% CAGR in FY1922E to | 5129 crore mainly on the back of new addition and improvement in...

Apollo Hospitals Ent.. has an average target of 7476.40 from 5 brokers.

Apollo Hospitals Enterprise Ltd.

10 Dec 2019

7051.00

0.59%

Hospital Sector Report

Buy: Apollo Hospitals Enterpris...

ICICI Securities Limited

In the last three to four years, with many frontline large cap pharma companies being hampered by structural US related & other issues, we have seen growing investors' preference for healthcare services providers. At the same time, as many as four hospitals and three diagnostic companies got listed on the bourses, thus providing a much larger basket for investors. Some peculiar factors responsible for growing interest in the hospitals space are: 1) waning high capex episodes of private hospitals after the 2008-18 capex cycle, 2) shifting focus towards assets light model for most hospital...

Geojit BNP Paribas downgraded Apollo Hospitals Enterprise Ltd. to Accumulate with a price target of 7757.0 on 16 Jun, 2025.

Apollo Hospitals Enterprise Ltd.

18 Nov 2019

7051.00

0.59%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

Recommendation Target

ICICI Securities Limited

Healthcare expansion moderates; focus on asset sweating Rapid expansion and maturity of older hospitals has kept the overall growth tempo at 12-14% per annum. However, constant addition is likely to put some pressure on EBITDA margins and return ratios in the short to medium term. Similarly, existing hospital margins are being compressed due to 1) regulation on stent/implants pricing, 2) negative GST impact and 3) higher guarantee fees to the doctors. However, in the past, the company has demonstrated its ability to balance between expansion and profitability. We...

Apollo Hospitals Ent.. has an average target of 7476.40 from 5 brokers.

Apollo Hospitals Enterprise Ltd.

29 Aug 2019

7051.00

0.59%

APOLLO HOSPITAL

Hold: Apollo Hospitals Enterpris...

Recommendation Target

Geojit BNP Paribas

Margins up strongly leading to PAT growth Net sales grew 16.8% YoY to Rs. 2,234cr in Q1FY20. EBITDA, adjusted for Ind AS 116 adoption, grew ~21.0% YoY to Rs. 274cr in Q1FY20. Adjusted EBITDA margin came in at 12.3% (up 43bps YoY) due to strong performance from mature hospitals, whose adjusted EBITDA margin stood at 22.1%. Adjusted EBITDA rose 21.0% YoY to Rs....

Apollo Hospitals Enterprise Ltd.'s price crossed above 50Day SMA today

Apollo Hospitals Enterprise Ltd.

16 Aug 2019

7051.00

0.59%

Apollo Hospitals

Hold: Apollo Hospitals Enterpris...

Recommendation Target

ICICI Securities Limited

Healthcare expansion moderates; focus on asset sweating Rapid expansion and maturity of older hospitals has kept overall growth tempo at 12-14% per annum. However, constant addition is likely to put some pressure on EBITDA margins and return ratios in the short to medium term. Similarly, existing hospital margins are being compressed due to 1) regulation on stent/implants pricing, 2) negative GST impact and 3) higher guarantee fees to the doctors. However, in the past, the company has demonstrated its ability to balance between expansion and profitability. We...

Geojit BNP Paribas downgraded Apollo Hospitals Enterprise Ltd. to Accumulate with a price target of 7757.0 on 16 Jun, 2025.

Apollo Hospitals Enterprise Ltd.

31 May 2019

7051.00

0.59%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

Target

ICICI Securities Limited

Geojit BNP Paribas downgraded Apollo Hospitals Enterprise Ltd. to Accumulate with a price target of 7757.0 on 16 Jun, 2025.

Apollo Hospitals Enterprise Ltd.

11 Feb 2019

7051.00

0.59%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

Target

ICICI Securities Limited

The Q3FY19 standalone operational performance was in line with Idirect estimates while net profit was lower mainly due to higher-thanexpected interest cost and depreciation Revenues grew 14.4% YoY to | 2169 crore (I-direct estimate: | 2145.8 crore) due to 13.9% growth in pharmacy to | 1011.9 crore (Idirect estimate: | 1043.2 crore) and 14.8% YoY growth in healthcare business to | 1157.3 crore (I-direct estimate: | 1102.8 crore) EBITDA margins improved 68 bps YoY to 12.3% (I-direct estimate: 12.6%) mainly due to lower other expenditure. EBITDA grew 21.1% YoY at | 267.9 crore (I-direct estimate: | 271.0 crore) Net profit grew 28.9% to | 86.9 crore (I-direct estimate: | 93.3 crore)...

Geojit BNP Paribas downgraded Apollo Hospitals Enterprise Ltd. to Accumulate with a price target of 7757.0 on 16 Jun, 2025.

Apollo Hospitals Enterprise Ltd.

16 Nov 2018

7051.00

0.59%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

Target

ICICI Securities Limited

Q2FY19 results were operationally in line with I-direct estimates. However, net profit was lower mainly due to lower other income and higher tax rate (33% vs. I-direct estimate of 21%) Revenues grew 12.9% YoY to | 2090 crore (I-direct estimate: | 2092.4 crore) on the back of 16.4% YoY growth in pharmacy...

Number of FII/FPI investors increased from 1501 to 1548 in Mar 2025 qtr.

Apollo Hospitals Enterprise Ltd.

14 Aug 2018

7051.00

0.59%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

Recommendation Target

ICICI Securities Limited

Standalone revenues grew 13.4% YoY to | 1910.4 crore (I-direct estimate: | 1921.6 crore) on the back of 16.7% YoY growth in the pharmacy business to | 892.1 crore (I-direct estimate: | 908.7 crore) and 10.7% YoY growth in the healthcare business to | 1019 crore (Idirect estimate: | 1013.2 crore) EBITDA margins improved 156 bps YoY to 11.9% (I-direct estimate: 11.5%) mainly due to lower other expenditure. EBITDA grew 30.5% YoY at | 226.7 crore (I-direct estimate: | 220.3 crore) Net profit grew 70.9% to | 60.2 crore (I-direct estimate: | 71.9 crore)...

Geojit BNP Paribas downgraded Apollo Hospitals Enterprise Ltd. to Accumulate with a price target of 7757.0 on 16 Jun, 2025.

Is Apollo Hospitals Enterprise Ltd. worth buying?

224 Votes:

Buy 70.98%

Sell 20.09%

Hold 8.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf